Department of Psychology, University of California, Los Angeles, Los Angeles, CA, United States; Brain Research Institute, University of California, Los Angeles, Los Angeles, CA, United States; Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, CA, United States. Electronic address: lararay@psych.ucla.edu.
Department of Psychiatry (Garrison, Sinha, Potenza), Child Study Center (Sinha, Potenza, Scheinost), n.; Department of Neuroscience (Sinha, Potenza), Wu Tsai Institute (Potenza, Scheinost), Department of Biomedical Engineering (Gao, Liang, Scheinost), and Department of Statistics and Data Science (Scheinost), Yale University, New Haven, Conn.; Connecticut Mental Health Center, New Haven, Conn. (Potenza); Connecticut Council on Problem Gambling, Hartford, Conn. (Potenza).
Department of Psychiatry (Garrison, Sinha, Potenza), Child Study Center (Sinha, Potenza, Scheinost), n.; Department of Neuroscience (Sinha, Potenza), Wu Tsai Institute (Potenza, Scheinost), Department of Biomedical Engineering (Gao, Liang, Scheinost), and Department of Statistics and Data Science (Scheinost), Yale University, New Haven, Conn.; Connecticut Mental Health Center, New Haven, Conn. (Potenza); Connecticut Council on Problem Gambling, Hartford, Conn. (Potenza).
Department of Psychiatry (Garrison, Sinha, Potenza), Child Study Center (Sinha, Potenza, Scheinost), n.; Department of Neuroscience (Sinha, Potenza), Wu Tsai Institute (Potenza, Scheinost), Department of Biomedical Engineering (Gao, Liang, Scheinost), and Department of Statistics and Data Science (Scheinost), Yale University, New Haven, Conn.; Connecticut Mental Health Center, New Haven, Conn. (Potenza); Connecticut Council on Problem Gambling, Hartford, Conn. (Potenza).
Department of Psychiatry (Garrison, Sinha, Potenza), Child Study Center (Sinha, Potenza, Scheinost), n.; Department of Neuroscience (Sinha, Potenza), Wu Tsai Institute (Potenza, Scheinost), Department of Biomedical Engineering (Gao, Liang, Scheinost), and Department of Statistics and Data Science (Scheinost), Yale University, New Haven, Conn.; Connecticut Mental Health Center, New Haven, Conn. (Potenza); Connecticut Council on Problem Gambling, Hartford, Conn. (Potenza).
Department of Psychiatry and Behavioral Sciences Johns Hopkins University School of Medicine, Baltimore, MD, United States. Electronic address: cberge21@jhmi.edu.
Neutrophil extracellular traps (NETs) may play a pathogenic role in the thrombosis associated with myeloproliferative neoplasms (MPNs). We measured serum NET levels in 128 pretreatment samples from pa...
The recombinant human interferon alpha-2b (IFN-α2b) nasal drop formulation (Nasalferon) was studied as prophylaxis for SARS-CoV-2. Healthy volunteers between 19 and 80 years of age received 0.5 millio...
The aim of this study was to report a case of ocular Mpox that responded favorably to treatment with topical interferon and oral doxycycline....
This is a case report of a previously healthy 24-year-old woman who developed a pustular rash, headache, fever, arthralgia, sore throat, and asthenia 3 weeks before attending to our clinic. Her main c...
Mpox with ocular manifestations diagnosis was confirmed by real-time quantitative reverse transcription polymerase chain reaction assay (qRT-PCR) testing; samples were taken from corneal, conjunctival...
Alternative and efficacious treatment options for Mpox ocular manifestations are needed to prevent further disease progression and sequelae in countries with no access to the gold-standard therapy. To...
The purpose of this study was to introduce the initial experience in the use of topical pegylated interferon alpha 2a (PegIFN-α-2a) for ocular surface squamous neoplasia (OSSN)....
A retrospective medical record review of 8 eyes of 8 patients diagnosed with OSSN and treated with PegIFN-α-2a was performed. All cases were diagnosed of noninvasive OSSN both clinically and histologi...
In all 8 cases, topical PegIFN-α-2a was well-tolerated and did not lead to discomfort or any adverse side effects. It resulted in reduction in lesion size and extent in all cases and complete resoluti...
Topical PegIFN-α-2a might be an effective and safe treatment option for noninvasive OSSN....
To report the efficacy and safety of 5-fluorouracil as the second line of treatment for two cases of conjunctival intraepithelial neoplasia refractive to topical interferon alpha-2b....
In the first case, a 77-year-old woman was evaluated because of a fleshy vascularized lesion in the temporal conjunctiva on her right eye with leukoplakia of the corneal epithelium from 10- to 5-o'clo...
In the absence of efficacy, the treatment was then changed to topical 5-fluorouracil (1%), 4 times/day for 7 days with a time-lapse of 21 days off, which constitutes a course. Two and four courses of ...
The treatment with 5-fluorouracil is a good option as the second line of treatment for conjunctival intraepithelial neoplasia who are low-responders to interferon alpha-2b, with fewer side effects tha...
The best antiviral treatment for chronic hepatitis B (CHB) poses a complex challenge. The treatment effect of the combination of nucleoside analogues (NAs) and pegylated interferon alpha (PegIFN) was ...
We studied patients treated with NAs and PegIFN-2b at our institution from November 2019 to January 2022. Logistic regression identified independent factors influencing clinical cure. The predictive a...
A total of 120 patients were enrolled in the final analysis. Among the cohort of patients under study, 71 (59.1%) patients had clinical cure while 49 (40.9%) patients did not. Hepatitis B surface anti...
This study provided predictive formulas for clinical cure, offering valuable insights for CHB treatment. PegIFN and NAs exhibited efficacy. Future research that explores additional factors, such as HB...
Ocular surface squamous neoplasia (OSSN) comprises a wide spectrum of squamous tumors, from which corneal/conjunctival intraepithelial neoplasia (CIN) is the most common one. The classic treatment is ...
Patients diagnosed with localized CIN were evaluated by slit lamp and impression cytology and were randomly given MMC 0.04% or INF2b (1 million IU/mL) 4 times daily until neoplasia resolution. Time of...
Seventeen patients were included. Nine patients were treated with MMC and 8 with IFNα2b. All patients responded to treatment. The resolution time in days was 59.11 ± 24.02 in patients treated with MMC...
Topical chemotherapy with MMC and IFNα2b demonstrate pharmacological safety and efficacy. Therefore, these drugs could be considered as primary therapies for localized CIN ....
Lack of appropriate process models, reliable online sensors, and process variability in bioprocess systems are poising challenges in real-time monitoring and control of critical process parameters (CP...
Recombinant interferon-α2a (IFNα2a) has been widely used in the treatment of Behcet's uveitis (BU). However, the mechanism underlying its effects remains poorly understood. In this study, we investiga...
Our aim was to give a comparative assessment of the effectiveness of using narlaprevir in combination with pegylated interferon-alpha-2a (Peg-IFN-alpha-2a) and interferon-free mode in patients with ch...
The prospective cohort study included 187 patients infected with genotype 1b of hepatitis C virus. Of these, 107 (the 1st group of patients) received narlaprevir 200 mg once a day, ritonavir 100 mg on...
With the use of an interferon-containing treatment regimen, a sustained virological response was achieved in 92.4% of previousle untreated patients with CH and in 66.7% patients with "unsuccessful" ex...
Real clinical practice indicates that the use of narlaprevir in the non-interferon mode is not inferior in efficiency to the interferon-containing treatment regimen and demonstrates a more favorable s...
